Medtronic has filed for 510(k) clearance from the FDA to expand the use of its Hugo surgical robot into general and gynecological procedures. This move aims to broaden Hugo's market reach beyond urological procedures, enabling Medtronic to better compete with Intuitive Surgical's da Vinci robots in major robotic surgery markets. The company noted that Hugo has already contributed to an 8% growth in its U.S. medical surgical sales in the fourth quarter.

Lam Research Corp (LRCX) stock dropped by 3.97% on June 4th, primarily due to U.S. restrictions on chip shipments to China's Hua Hong, impacting U.S. chip equipment manufacturers. Broader market declines, geopolitical tensions in the Middle East, rising oil prices, and an increase in the VIX also contributed to the downward pressure. Additionally, some analyses suggest the stock may be overvalued, and recent insider selling activity and a downgrade by Erste Group further impacted investor confidence.

Parabilis Medicines (PBLS), a cancer drug developer with a research collaboration with Regeneron (REGN), is aiming to raise up to $476 million in its initial public offering in the U.S. This information comes from an amended S-1 filing.

Somnigroup International has successfully cleared the US antitrust waiting period for its $2.5 billion acquisition of Leggett & Platt. The transaction is expected to close by year-end 2026, pending shareholder and international regulatory approvals. Upon completion, Leggett & Platt will operate as a separate business unit within Somnigroup, with existing leadership and operations largely maintained.

State Street Corporation has announced a strategic partnership with Principal Financial Group to provide custody, fund accounting, and administrative services for Principal Funds. This collaboration aims to leverage State Street's extensive platform and global resources to support Principal Financial Group's growth, particularly in retirement and asset management. Despite a strong GF Score™ of 80/100, STT's current valuation, with a P/E ratio near its 5-year high, and recent insider selling suggest caution for investors.

Benchmark Equity Research initiated coverage of CoStar Group (NASDAQ: CSGP) with a Buy rating and a $45 price target, believing the stock has bottomed out after a 50% year-to-date decline driven by housing concerns, Homes.com spending, and activist investor noise. Analyst Michael Rindos expects CoStar's residential segment adjusted EBITDA to turn positive in the second half of 2026, with margins expanding into 2027. Despite past investor criticism, Benchmark supports CoStar's strategy, highlighting its dominant position in commercial real estate and subscription-based revenue model.

FICO (NYSE: FICO) has announced the integration of its FICO Score 10T into Optimal Blue's platform, a strategic move expected to enhance mortgage lending capabilities by enabling lenders to more effectively price and evaluate non-agency loans. The company boasts a strong GF Score™ of 83/100, driven by exceptional profitability and growth, despite insider selling activities.

UnitedHealth Group stock surged over 5% after Bank of America upgraded the managed care giant from Neutral to Buy, raising its price target to $450. The upgrade was attributed to UNH's strong first-quarter performance, improving medical cost trends, and the company's strategic overhaul, which includes investments in AI and a strong earnings outlook. This positive sentiment, combined with the stock being technically oversold, drove the rally.

This article compares Altria (MO) and Philip Morris International (PM), two tobacco giants, focusing on their business models, financial health, and dividend metrics to determine which is a stronger buy. While Altria offers a higher dividend yield and lower P/E, Philip Morris International boasts a larger global footprint, stronger sales growth, and a clearer long-term strategy centered on smoke-free products. The author concludes that Altria is better for income-focused investors, while Philip Morris is more compelling for those prioritizing business quality and long-term positioning.

This SEC Form 144 filing for Nordson Corp (NDSN) details a proposed sale of 6,600 shares of common stock with an aggregate market value of $1,914,000.00. The shares were acquired through a stock option exercise on June 4, 2026, and are intended to be sold on NASDAQ on the same date via Fidelity Brokerage Services LLC. The filing confirms no previous sales by the filer in the past three months and includes a representation that no material adverse information is known regarding Nordson's operations.